ESSENCE

Last week, Sarepta Therapeutics Inc (NASDAQ: SRPT)'s Phase 3 ESSENCE study was updated and extended from 48 to 96 weeks. To many, the extension of the endpoint signaled a lack of confidence in the study's readout, however Baird thinks otherwise. Baird's Interpretation Despite the market's bearish...